A vaccination update for rheumatologists-SARS-CoV-2, influenza and herpes zoster.
作者信息
Wong Peter K K, Lahiri Manjari, Lye David Chien, Johnson Douglas, Charles Patrick G P
机构信息
Department of Rheumatology, Westmead Hospital, Sydney, NSW, Australia.
Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
出版信息
Int J Rheum Dis. 2021 Aug;24(8):979-983. doi: 10.1111/1756-185X.14179.
Abstract
摘要
相似文献
1
A vaccination update for rheumatologists-SARS-CoV-2, influenza and herpes zoster.
Int J Rheum Dis. 2021 Aug;24(8):979-983. doi: 10.1111/1756-185X.14179.
2
Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist.
Rheum Dis Clin North Am. 2017 Feb;43(1):1-13. doi: 10.1016/j.rdc.2016.09.003. Epub 2016 Oct 22.
3
2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.
Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.
4
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.
Ann Rheum Dis. 2021 Oct;80(10):1255-1265. doi: 10.1136/annrheumdis-2021-221244. Epub 2021 Sep 7.
5
Herpes zoster infection, vaccination and immunocompromised rheumatology patients.
Rheumatol Int. 2013 Jan;33(1):239-40. doi: 10.1007/s00296-011-2155-9. Epub 2011 Sep 24.
6
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
Ann Rheum Dis. 2021 Oct;80(10):1357-1359. doi: 10.1136/annrheumdis-2021-220604. Epub 2021 May 11.
7
COVID-19 and rheumatology: Reflecting on the first wave and preparing for the second wave.
Int J Rheum Dis. 2021 Jan;24(1):7-9. doi: 10.1111/1756-185X.14062.
8
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
Ann Rheum Dis. 2021 Oct;80(10):1355-1356. doi: 10.1136/annrheumdis-2021-220408. Epub 2021 May 6.
9
Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
Vaccine. 2018 Jan 2;36(1):179-185. doi: 10.1016/j.vaccine.2017.08.029. Epub 2017 Aug 19.
10
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
Ann Rheum Dis. 2021 Oct;80(10):1330-1338. doi: 10.1136/annrheumdis-2021-220647. Epub 2021 Jun 14.
引用本文的文献
1
Effectiveness of recombinant zoster vaccine in reducing herpes zoster incidence and all-cause mortality among patients with rheumatoid arthritis: a retrospective cohort study of 21,046 individuals from TriNetX U.S. Collaborative Network.
EClinicalMedicine. 2025 Jun 25;85:103319. doi: 10.1016/j.eclinm.2025.103319. eCollection 2025 Jul.
本文引用的文献
1
Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial.
Lancet Rheumatol. 2020 Jan;2(1):e14-e23. doi: 10.1016/S2665-9913(19)30094-3. Epub 2019 Nov 20.
2
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2.
Arthritis Rheumatol. 2021 Aug;73(8):e30-e45. doi: 10.1002/art.41877. Epub 2021 Jun 15.
3
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.
Ann Rheum Dis. 2021 Oct;80(10):1339-1344. doi: 10.1136/annrheumdis-2021-220597. Epub 2021 May 25.
4
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
5
Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists.
Int J Rheum Dis. 2021 Jun;24(6):746-757. doi: 10.1111/1756-185X.14107. Epub 2021 May 10.
6
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
Gut. 2021 Oct;70(10):1884-1893. doi: 10.1136/gutjnl-2021-324789. Epub 2021 Apr 26.
7
COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.
J Korean Med Sci. 2021 Mar 29;36(12):e95. doi: 10.3346/jkms.2021.36.e95.
8
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
Ann Rheum Dis. 2021 Oct;80(10):1306-1311. doi: 10.1136/annrheumdis-2021-220272. Epub 2021 Mar 24.
9
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.
Ann Rheum Dis. 2021 Aug;80(8):1098-1099. doi: 10.1136/annrheumdis-2021-220289. Epub 2021 Mar 23.
10
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.
JAMA. 2021 May 4;325(17):1784-1786. doi: 10.1001/jama.2021.4385.
Zotero 插件